• Orthocell reaches 100 unit sales of its Remplir nerve repair product in the US
• Successful uptake driven by medical education campaign and distributor network
• 17 hospital Value Analysis Committee approvals secured ahead of schedule

Orthocell Limited (ASX:OCC) has reached 100 unit sales in the US of its flagship nerve repair product, Remplir, marking a key early adoption milestone in the US$1.6 billion US nerve repair market. The successful surgical uptake reflects growing momentum in the US rollout, driven by a combination of Orthocell's concerted medical education and awareness campaign and a specialist distributor network across 25 states covering 40% of the US population. To date, Orthocell has engaged over 250 surgeons from medical education programs, and has 14 Medical Advisory Board members under contract. The milestone follows 61 active submissions to US hospital Value Analysis Committees (VACs), with 17 approvals secured ahead of schedule. VAC approvals are critical to facilitate access and sales within hospital networks. The expanding US surgical experience will also be leveraged to support international growth, including first Remplir surgeries in Canada planned for early 2026. Orthocell remains focused on driving rapid market adoption of Remplir, supported by a strong balance sheet and ongoing investment in clinical evidence and medical education initiatives.

Orthocell targets a Total Addressable Market (TAM) in selected jurisdictions of more than US$3.5 billion for its nerve repair products.

Orthocell sees significant upside in the US market if it continues on the current trajectory of early surgical adoption and hospital approvals. The Company is focused on driving rapid market adoption of Remplir to support anticipated growth in the US during 2026 and the commencement of first surgeries in Canada in early 2026.